Looking after the overlooked

Theratechnologies is a commercial-stage biopharmaceutical company. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV and oncology.

Most recent

February 18, 2020

Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019

February 04, 2020

Theratechnologies signs agreements with Massachusetts General Hospital and Dr. Steven Grinspoon

December 19, 2019

Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

Making a difference

Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing niche therapeutic needs.

Our values


The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.


There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.


We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our commercialized products

Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SVTM is approved in the United States while EGRIFTA® is approved in the United States, Canada and Mexico.